Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Balance Sheets

v3.10.0.1
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2018
Dec. 31, 2017
Current assets:    
Cash and cash equivalents $ 66,028 $ 79,223
Short-term investments 298,515 86,873
Restricted cash - short-term 194 194
Prepaid expenses and other current assets 8,239 5,900
Total current assets 372,976 172,190
Property and equipment, net 68,279 44,129
Restricted cash - long-term 1,200 1,200
Other assets 485 260
Total assets 442,940 217,779
Current liabilities:    
Accounts payable 6,193 14,711
Accrued compensation 9,072 5,664
Accrued research and development expenses 3,803 4,006
Other current liabilities 7,932 3,265
Total current liabilities 27,000 27,646
Long-term liabilities 12,886 12,269
Total liabilities 39,886 39,915
Commitments and contingencies (Note 7)
Stockholders’ equity:    
Common stock—$0.0001 par value, 500,000 shares authorized as of September 30, 2018 and December 31, 2017; 45,645 and 30,730 shares issued and outstanding as of September 30, 2018 and December 31, 2017, respectively 5 3
Additional paid-in capital 850,835 474,662
Accumulated other comprehensive loss (449) (151)
Accumulated deficit (447,337) (296,650)
Total stockholders’ equity 403,054 177,864
Total liabilities and stockholders’ equity $ 442,940 $ 217,779